Argus Adjusts IQVIA Holdings Price Target to $245 From $260, Maintains Buy Rating
TD Cowen Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $250
TD Cowen Sticks to Its Buy Rating for IQVIA Holdings (IQV)
IQVIA Hldgs Analyst Ratings
Citi Maintains IQVIA Holdings(IQV.US) With Hold Rating, Cuts Target Price to $210
Citigroup Adjusts Price Target on IQVIA Holdings to $210 From $225, Maintains Neutral Rating
J.P. Morgan Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $232
IQVIA Holdings (IQV) Receives a Buy From J.P. Morgan
JP Morgan Maintains Overweight on IQVIA Hldgs, Lowers Price Target to $232
IQVIA Hldgs Analyst Ratings
IQVIA Hldgs Analyst Ratings
Morgan Stanley Maintains Overweight on IQVIA Hldgs, Raises Price Target to $250
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Insmed (INSM) and IQVIA Holdings (IQV)
RBC Capital Reiterates Outperform on IQVIA Hldgs, Maintains $270 Price Target
Morgan Stanley Maintains IQVIA Holdings(IQV.US) With Buy Rating, Raises Target Price to $250
RBC Capital Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $270
Truist Financial Maintains IQVIA Holdings(IQV.US) With Buy Rating, Announces Target Price $263
Truist Financial Reaffirms Their Buy Rating on IQVIA Holdings (IQV)
TD Cowen Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $250
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $220 to $261